mCRPC
mCRPC
Metastatic castration-resistant prostate cancer
Advertisement
Emily MenendezmCRPC | March 23, 2023
A recent study compared the activity of taxanes with second-line androgen-receptor therapy in patients with mCRPC.
Read More
Alan H. Bryce, MDASCO GU Symposium 2023 | February 17, 2023
Alan H. Bryce, MD, highlights the positive TRITON3 data for rucaparib as a new standard of care for patients with mCRPC.
Emily MenendezASCO GU Symposium 2023 | February 17, 2023
At the 2023 ASCO GU Symposium, Alan Bryce, MD, presented results from the TRITON3 study on rucaparib vs physician’s choice.
Noel Clarke, MBBS, FRCS, ChMASCO GU Symposium 2023 | February 17, 2023
Noel Clarke, MBBS, FRCS, ChM, explains the PROpel study design and what the overall survival data shows at data cutoff 3.
Neeraj Agarwal, MDASCO GU Symposium 2023 | February 16, 2023
Neeraj Agarwal, MD, highlights the significance of TALAPRO-2 in mCRPC and the data for rPFS with respect to HRR status.
Zachary BessetteASCO GU Symposium 2023 | February 16, 2023
A new study examined the relationship between pathogenic germline BRCA2 mutation and somatic change in circulating tumor DNA.
Emily MenendezASCO GU Symposium 2023 | February 16, 2023
A study reviewed the prognostic value of neuroendocrine differentiation in mCRPC patients receiving abiraterone or docetaxel.
Tanya Dorff, MDmCRPC | February 13, 2023
Dr. Tanya Dorff highlights the mCRPC treatment approaches worth monitoring, including sequential and combination strategies.
Tanya Dorff, MDmCRPC | February 13, 2023
Tanya Dorff, MD, provides an overview of the latest data for PARP inhibitor plus AR-targeted agents for patients with mCRPC.
Emily MenendeznmCRPC | February 9, 2023
Existing literature on adverse events in ARSi drugs was examined to determine how the drugs’ side-effect profiles compare.
Emily MenendezmCRPC | February 1, 2023
A study compared the gross and OOP payments for 6 different first-line mCRPC drugs during the 6 months post-treatment start.
Zachary BessettemCRPC | January 9, 2023
Medicare beneficiaries with metastatic prostate cancer incurred additional average costs of over $30,000 annually.
Emily MenendezmCRPC | January 4, 2023
Liquid biopsy of CTCs may serve as an effective prediction biomarker for docetaxel response in patients with CRPC and mHSPC.
Zachary BessettemCRPC | December 15, 2022
A new study examined the efficacy of abiraterone, enzalutamide, and docetaxel in patients with BRCA-positive mCRPC.
Emily MenendezmCRPC | December 5, 2022
Further study is needed to determine if certain biomarkers can aid in determining effectiveness and safety.
Emily MenendezmCRPC | November 17, 2022
Olaparib is the first and only PARP inhibitor to be approved for use in the EU for the treatment of prostate cancer patients.
Emily MenendezRLT-PSMA | November 14, 2022
The phase 2 TheraP trial found that higher gallium-68–labeled PSMA-11-PET SUVmean had a higher chance of PSA response.
Emily MenendezRLT-PSMA | November 14, 2022
Studies have investigated the effects of 177Lu-PSMA and 225Ac-PSMA RNT in mCRPC patients, with promising treatment results.
Leah LawrencemCRPC | October 25, 2022
Olaparib with cediranib significantly improved rPFS in men with mCRPC, but was associated with an increase in adverse events.
Akhil Abraham Saji, MDJournal | October 24, 2022
Results from the phase 3 PROpel trial on abiraterone + olaparib vs abiraterone + placebo as first-line therapy for MCRPC
Advertisement
Advertisement
Advertisement